

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
CONSUN PHARMACEUTICAL GROUP LIMITED

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

**RESIGNATION OF EXECUTIVE DIRECTOR  
AND CHIEF EXECUTIVE OFFICER  
AND  
CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE**

**RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. LI Qian (“**Ms. Li**”) has resigned from the position of an executive Director of the Company, vice chairlady of the Board, the chief executive officer, a member of the remuneration committee of the Company (the “**Remuneration Committee**”) and all other positions with the Group with effect from 17 January 2024, due to health reasons.

Ms. Li has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

The Company announces that Mr. An Meng, the Chairman of the Board and an executive Director, has been appointed as the chief executive officer with effect from 17 January 2024.

Pursuant to code provision C.2.1 of the Corporate Governance Code in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), the roles of chairman and the chief executive officer should be separate and should not be performed by the same individual. Despite the deviation from C.2.1 of the code provision of the Listing Rules for Mr. An Meng serves as the Chairman of the Board as well as the chief executive officer of the Company, the Board believes that Mr. An Meng being the Chairman of the Board, is familiar with the Company’s business operation and has excellent knowledge and experience of the Company’s business which will be conducive to improving the efficiency of the Company’s overall strategic planning. The Board believes that such management structure layout will be more beneficial to the future development of the Company and will improve the Company’s operating conditions. Under the supervision of the Board which will comprise of three executive Directors, one non-executive Director and three independent non-executive Directors, the Board is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and its shareholders.

## **CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE**

With effect from 17 January 2024 and following the resignation of Ms. Li, Mr. An Meng has been appointed to be a member of the Remuneration Committee in place of Ms. Li.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Ms. Li towards the Company during her tenure of office.

By order of the Board of  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 17 January 2024

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Xu Hanxing as executive Directors; Doctor Zhang Lihua as a non-executive Director; and Mr. Su Yuanfu, Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive Directors.*